Phase 1 Dose-Escalation Study of the Rapid-Clearance Radioligand [ 177 Lu]Lu-P17-087 in Metastatic Castration-Resistant Prostate Cancer: Dosimetry, Safety, and Preliminary Efficacy

医学 药代动力学 不利影响 不良事件通用术语标准 前列腺癌 放射性配体 淋巴结 肿瘤科 内科学 药效学 临床研究阶段 药理学 谷氨酸羧肽酶Ⅱ 泌尿科 前列腺 养生 前列腺特异性抗原 癌症 闪烁照相术 淋巴 药品 进行性疾病 放射性核素治疗 胃肠病学 抗原 生物标志物 分布(数学) 肾 病理
作者
Ruiyue Zhao,Mingzhao Li,Jie Lv,Jing Zhang,Huizhen Zhong,Yimin Fu,Jinhui Liu,Di Gu,Guohua Zeng,Hank F. Kung,Lin Zhu,Jinkun Huang,Xinlu Wang
出处
期刊:Journal of nuclear medicine [Society of Nuclear Medicine and Molecular Imaging]
卷期号:: jnumed.126.272406-jnumed.126.272406
标识
DOI:10.2967/jnumed.126.272406
摘要

Given the rapid systemic clearance and favorable kinetic profile of the novel DOTA(GA)2-conjugated ligand [177Lu]Lu-P17-087, this phase 1 study aimed to systematically evaluate the safety, pharmacokinetics, dosimetry, and preliminary antitumor activity of escalating therapeutic activities in patients with metastatic castration-resistant prostate cancer (mCRPC). Methods: Nine patients with progressive mCRPC and high prostate-specific membrane antigen (PSMA) expression on PET/CT were enrolled. An adaptive intrapatient dose-escalation protocol was used, with administered activities categorized as low (1.1–2.3 GBq), mid (3.7–5.6 GBq), and high (∼7.4 GBq). Serial whole-body planar scintigraphy (1–96 h postinjection) and quantitative SPECT/CT (24 h postinjection) were acquired for dosimetry analysis using OLINDA/EXM. Safety was assessed per Common Terminology Criteria for Adverse Events version 5.0. Antitumor efficacy was evaluated by prostate-specific antigen (PSA) response and radiographic response using PSMA PET/CT (RECIP 1.0). Activity-associated PSA changes were summarized descriptively across administered activity levels. Results: [177Lu]Lu-P17-087 exhibited rapid pharmacokinetics (effective half-life of 0.52 h in blood). This fast-clearance profile yielded low absorbed doses to dose-limiting organs, including the kidneys (0.39 ± 0.26 Gy/GBq) and red marrow (0.07 ± 0.01 Gy/GBq). Conversely, lesions showed sustained retention, particularly in lymph node metastases (half-life, 22.9 h). The dose-escalation regimen was well tolerated; no dose-limiting toxicities or grade 3/4 hematologic adverse events were observed, even at the maximum administered activity of 7.4 GBq. Biochemical response was observed in most patients, with 8 of 9 (88.9%) demonstrating a decline in PSA levels from baseline. A 50% decline from baseline in PSA was achieved in 2 of 9 patients (22.2%). The magnitude of PSA reduction varied across administered activity levels. Conclusion: This phase 1 dose-escalation study showed rapid in vivo clearance of [177Lu]Lu-P17-087 and low early normal-organ toxicity in this small cohort. Administration of activities up to 7.4 GBq per cycle was feasible and was associated with preliminary antitumor activity. Larger studies with longer follow-up are required to define efficacy, safety, and the optimal dosing strategy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
1秒前
bkagyin的应助被Xcentimeter采纳,获得10
1秒前
2秒前
2秒前
Ranann发布了新的文献求助10
2秒前
Ph完成签到 ,获得积分10
3秒前
wlw66发布了新的文献求助50
3秒前
我是老大的应助被痴情志浩采纳,获得10
4秒前
汉堡包的应助被蕾梅黛丝采纳,获得10
4秒前
CipherSage的应助被淳于友琴采纳,获得10
4秒前
春藏小松子完成签到,获得积分10
4秒前
黑猫黑猫发布了新的文献求助10
4秒前
noseven的应助被牧青采纳,获得10
5秒前
酷波er的应助被牧青采纳,获得10
5秒前
风趣的惠发布了新的文献求助10
5秒前
iedq完成签到 ,获得积分0
5秒前
隐形曼青的应助被牧青采纳,获得10
5秒前
Ava的应助被牧青采纳,获得10
5秒前
余正扬完成签到 ,获得积分10
5秒前
科研通AI6.4的应助被牧青采纳,获得10
5秒前
5秒前
Akim的应助被牧青采纳,获得10
6秒前
Gp1983的应助被牧青采纳,获得50
6秒前
俗签发布了新的文献求助10
6秒前
Gp1983的应助被牧青采纳,获得50
6秒前
一颗杨桃完成签到,获得积分10
6秒前
wanci的应助被bright采纳,获得10
7秒前
华仔的应助被高强采纳,获得10
7秒前
MingY完成签到,获得积分10
7秒前
7秒前
7秒前
mzc发布了新的文献求助10
8秒前
棉裤完成签到,获得积分10
8秒前
爆米花的应助被ciao采纳,获得10
8秒前
8秒前
搞怪朝雪发布了新的文献求助10
8秒前
04d的应助被闭上眼睛采纳,获得10
8秒前
怕黑明雪完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160268
求助须知:如何正确求助?哪些是违规求助? 9555328
关于积分的说明 21727231
捐赠科研通 7750062
什么是DOI,文献DOI怎么找? 3427353
关于科研通互助平台的介绍 2552391
邀请新用户注册赠送积分活动 2471707